RESUMO
OBJECTIVE: Hyperglycemia worsens outcomes in critical illness. This randomized, double-blind, placebo-controlled clinical trial tested whether insulin treatment of hyperglycemia during cardiopulmonary bypass would reduce neurologic, neuro-ophthalmologic, and neurobehavioral outcomes after coronary artery bypass grafting. METHODS: Three hundred eighty-one nondiabetic patients undergoing isolated coronary artery bypass grafting were given infusions of insulin or placebo when their blood glucose concentration exceeded 100 mg/dL during cardiopulmonary bypass. The primary outcome measure was the combined incidence of new neurologic, neuro-ophthalmologic, or neurobehavioral deficits or neurologic death observed at 4 to 8 days postoperatively. This same measure was assessed secondarily at 6 weeks and 6 months. Length of hospital stay was also compared as a secondary assessment. RESULTS: The 2 groups were well matched at baseline. The insulin-treated group had significantly lower blood glucose concentrations during bypass. Sixty-six percent of subjects in the insulin-treated group and 67% of subjects in the control group demonstrated a new or worsening neurologic, neuro-ophthalmologic, or neurobehavioral deficit or neurologic death at the 4- to 8-day assessment. Outcomes were also similar in the 2 groups at 6 weeks (37% and 39% incidence, respectively) and 6 months (30% and 25%, respectively). Median lengths of stay were 7 and 6 days, respectively, in the treatment and control groups. None of these outcome differences was statistically significant. CONCLUSION: Attempted control of hyperglycemia during cardiopulmonary bypass had no significant effect on the combined incidence of neurologic, neuro-ophthalmologic, or neurobehavioral deficits or neurologic death and failed to shorten the length of hospital stay. These results do not contradict those of other studies showing that aggressive control of hyperglycemia in the postoperative period will improve outcome.
Assuntos
Ponte Cardiopulmonar , Ponte de Artéria Coronária , Hiperglicemia/prevenção & controle , Transtornos Mentais/prevenção & controle , Doenças do Sistema Nervoso/prevenção & controle , Idoso , Ponte Cardiopulmonar/efeitos adversos , Ponte de Artéria Coronária/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Hiperglicemia/complicações , Insulina/uso terapêutico , Masculino , Transtornos Mentais/etiologia , Pessoa de Meia-Idade , Doenças do Sistema Nervoso/etiologia , Falha de TratamentoRESUMO
Vestibular symptoms such as vertigo and dizziness are quite common in migraine. There is no specific category in the new International Headache Society Classification for vestibular migraine. However, given the symptomatology often described, it would fit best under basilar-type migraine, even though by definition monosymptomatic attacks with rotational vertigo for a few seconds to minutes do not strictly fit the criteria. Vestibular migraine must be regarded as a migraine equivalent because it is a prominent symptom in many migraineurs.
Assuntos
Transtornos de Enxaqueca , Vertigem , Humanos , Transtornos de Enxaqueca/diagnóstico , Transtornos de Enxaqueca/etiologia , Transtornos de Enxaqueca/fisiopatologia , Vertigem/diagnóstico , Vertigem/etiologia , Vertigem/fisiopatologiaAssuntos
Adesivos/toxicidade , Hexanos/toxicidade , Polineuropatias/induzido quimicamente , Transtornos Relacionados ao Uso de Substâncias/complicações , Adolescente , Feminino , Transtornos Neurológicos da Marcha/induzido quimicamente , Humanos , Paresia/induzido quimicamente , Polineuropatias/sangue , Polineuropatias/patologia , Saúde Pública , Fatores de TempoRESUMO
Botulinum toxin type A (Botox) is increasingly used in the management of migraine and tension-type headaches. The results from small placebo-controlled trials and extensive open-label experience has suggested a significant role for this neurotoxin in the management of refractory headache. Several large placebo-controlled trials of episodic and chronic migraine are currently underway.